Dechra Pharmaceuticals Share Discussion Threads

[steeplejack] 18/7/2022 08:38

.......being nannied by the state in all things

[steeplejack] 18/7/2022 08:35

"As much as we love......." being nannied by the state,being told when to exercise,not to exercise,apply sun cream,wash,pay our taxes,open our minds to wokey dictates in which we have no interest,work from home,go to the office and generally being told how to live or ultimately die by our media corporations and government.

[johnrxx99] 12/7/2022 06:32

Agreed. We love our dog as much as we love ...........?

[steeplejack] 11/7/2022 07:04

Solid update and a reasonably mature market reaction in these feral times.

[daisylove] 18/5/2022 09:55

Took a position here. Seems to be a bit of momentum behind it.
PE now 30.
A beaten down mega-cap stock that will always be around.

[montyhedge] 09/5/2022 13:29

rogue
Your right, very high p.e stocks with tiny dividends, not the place to be, low p.e high dividend payers, rotation still going on.

[roguetraderuk] 04/5/2022 17:44

st, the ones you mention are all high multiple names esp for the uk mkt. when price of money is repriced so are these. on top of that youve got extra risk repricing from the back end of covid and the war which is leading to a global economic slowdown. ive never been able to buy halma over the years, i always ended up picking up something similarly positioned re growth. most recently during the covid drop i weighed up halma and ashtead, plumping for the latter eventually. now out of that and looking for a re entry at some point this year. but the point is the high multiple names dont tend to work when yields are going up. eventually they will stop and thats the time to step in imo.

[steeplejack] 04/5/2022 17:16

I suppose Dechra is something of a covid play in that pet ownership increased significantly during the epidemic.Will owners abandon their furry four legged friends now the epidemic is tailing off?Unlikely i would have thought.This company is an obvious beneficiary of sterling weakness of course.Sterling has weakened over ten cents or some 9% since the interim stage but the market is ignoring that.Sadly,Dechra is vulnerable to general disillusionment with equities along with the likes of Croda,Halma etc which similarly still well up on where they were trading a couple of years ago.There's a strong case for simply shoving off for the Summer and ignoring equity markets.There are too many negative headwinds,algorithmic trading dominating day to day trading.It's impossible to rationalise some of the price moves dictated as they are by a simple deleveraging of markets.

[spyder] 03/5/2022 16:48

Is FTSE 100 relegation an issue? They narrowly avoided it last time due to the sudden implosion of the Russia related stocks, but may not be so lucky this time around?

[roguetraderuk] 03/5/2022 15:57

its been a covid play on people buying pets, given 85% of revs are for domestic animals. and the higher multiple means its also getting pressure from that. but its one to buy if they overdo the downside imo.

[red5] 03/5/2022 15:33

This one has gone down a lot can I ask why? is there any trouble with this company?

[steeplejack] 14/4/2022 15:37

Ah there’s a sale of 92/- odd….that might explain it.Pretty lousy price achieved.

So on reflection,it looks like some fund manager found himself compelled to sell stock on the last trading day before Easter as a result perhaps of redemption requirements,a sudden bout of nerves,a damascene experience or simple stupidity.For whatever reason selling some 4 million quids worth of Dechra on the afternoon before a bank holiday in a quiet market smacks of irresponsibilityR30;.. but who knows what the future holds.

[steeplejack] 14/4/2022 15:36

Yes but requirements are that an RNS must be made in regard of director sales and there isn’t any RNS in respect of a sale by Dechra’s finance director.A fee based service can’t and won’t have privileged information which is not freely available so there is NO director sale as far as i’m concerned.The volume this afternoon is pretty low but there maybe more volume announced after hours and perhaps the MMs were working(rather badly)a big sell order.We’ve had falls like this before over the years.Normally some bored johnny comes up with the idea that Dechra is rather highly rated and gives it a kicking while most of the City are stuck on motorways and airports..

[toulston] 14/4/2022 15:26

Hi Steeplejack, I think you are correct there is just the non ex purchase of 2346 shares. Th announcement is a ALNC source that reports the CRH director selling 1.4 m of shares. The announcement must mention Dechra in the same report which is why it appeared on the Dechra news feed, this is a fee base source so cannot be certain, but that is what has coursed the confusion. That's my guess.

[roguetraderuk] 14/4/2022 15:10

block listing in regard to april 1st rns

[steeplejack] 14/4/2022 13:46

CRH is a Dublin based building company.Thereagain,someones selling Dechra.

[steeplejack] 14/4/2022 13:38

All i've got is a "CRH finance director "selling on advfn and nothing on company's website

[steeplejack] 14/4/2022 13:34

Dechra Pharmaceuticals PLC has been notified that on 5 April 2022 Alison Platt, Non-Executive Chair, purchased 2346 shares at £42.298pI can't find a sale.

[zydecoco] 14/4/2022 13:30

Financial Director sold - see RNS 5th April

[steeplejack] 14/4/2022 13:29

What director sale?

[montyhedge] 14/4/2022 12:09

Director sold always a bell ringing moment to follow a director.

[steeplejack] 04/4/2022 09:47

Dechra buy tip in Sun Times 3rd April

[blondviking] 24/2/2022 08:56

Only Blue on a down day!

[km18] 21/2/2022 13:18

Dechra Pharmaceuticals issued its HY Financial Report this morning. Reported Group revenue for the period increased by 15.9% to £332.4m at Constant Exchange Rate (CER). Underlying operating profit growth was 22.0% with underlying operating margin improving by 140 bps to 28.2%. Underlying diluted EPS growth was 24.0% to 64.01p and the interim dividend increased by 8.0% to 12 pence. So more robust growth and more profitable growth.

The business has been growing briskly and profitably for many years now and looks set to continue this pattern in FY22 as well. Unsurprisingly investors have already bought into the story, valuation is rich with forward PE ratio around 31 and bottom quartile for the Pharma sector. The share price is also currently in a 30%+ correction and still falling after a powerful post-Covid rally. DPH is a very good company delivering persistent and robust growth, but there is no rush to buy. Monitor for the time being....

...from WealthOracleAM

[spyder] 21/2/2022 11:44

I’m not going to lie, the market response to the results KBIS very disappointing.
Dechra now at significant risk of dropping out of the FTSE, that is a worry for obvious reasons.